Sulindac

• Description:

  Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer[1][2].

• Product Name Alternative:

  MK-231

• UNSPSC:

  12352005

• Hazard Statement:

  H301, H317, H334, H361

• Target:

  NF-κB; PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Sulindac.html

• Purity:

  99.68

• Solubility:

  DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL

• Smiles:

  O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O

• Molecular Formula:

  C20H17FO3S

• Molecular Weight:

  356.41

• Precautions:

  H301, H317, H334, H361

• References & Citations:

  [1]Byong-Ki Cha, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7 (35) :57213-57227. |[2]Bin Yi, et al. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Mol Cancer Ther. 2021 Jul;20 (7) :1295-1304.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  COX-2

• CAS Number:

  [38194-50-2]